Press Releases

Media Inquiries - media@caredxinc.com

Date	Title and Summary	Additional Formats
Toggle Summary Mar 20, 2020	New AJT Publication: AlloSure Monitors First Patient Retransplanted After Anti-PD-L1 Cancer Therapy CareDx Congratulates Johns Hopkins on Successful Follow-Up Using AlloSure of First Retransplant Patient After Immunotherapy SOUTH SAN FRANCISCO, Calif. , March 19, 2020 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and	View HTML
Toggle Summary Mar 17, 2020	CareDx Launches RemoTraC: Home-Based Monitoring of Transplant Patients CareDx brings remote solutions to the immunosuppressed transplant community to address COVID-19 concerns SOUTH SAN FRANCISCO, Calif. , March 17, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of	View HTML
Toggle Summary Mar 12, 2020	CareDx Joins National Kidney Foundation on World Kidney Day to Support Kidney Transplant Community CareDx CMO to Chair Upcoming NKF San Francisco Kidney Walk SOUTH SAN FRANCISCO, Calif. , March 12, 2020 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leader in precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high value	View HTML
Toggle Summary Mar 05, 2020	CareDx Brings Personalized Care to Transplant with the Launch of KIRA Immuno-optimization Study at CEOT CareDx Brings a Leading Presence to the Cutting Edge of Transplantation Meeting with a New AJT Publication and KIRA Study Announcement SOUTH SAN FRANCISCO, Calif. , March 05, 2020 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leader in molecular diagnostics focused on the discovery,	View HTML
Toggle Summary Feb 28, 2020	CareDx to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today	View HTML
Toggle Summary Feb 27, 2020	CareDx Reports Fourth Quarter and Full Year 2019 Results SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high value healthcare solutions for transplant patients and caregivers, today	View HTML
Toggle Summary Feb 26, 2020	New AJT Publication: AlloSure is the Only cfDNA Test Proven to Differentiate Ambiguous Rejections CareDx Publishes Data in American Journal of Transplantation that can Change the Paradigm of Care for Transplant Patients SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and	View HTML
Toggle Summary Feb 13, 2020	CareDx to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020 SOUTH SAN FRANCISCO, Calif. , Feb. 13, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today	View HTML
Toggle Summary Feb 11, 2020	CareDx’s Patent Rights Upheld By Delaware Court IP decision follows recent success in false advertising case SOUTH SAN FRANCISCO, Calif. , Feb. 11, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value	View HTML
Toggle Summary Feb 04, 2020	CareDx Launches AiTraC Conference CareDx’s transplant specific algorithms enable personalized care SOUTH SAN FRANCISCO, Calif. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value	View HTML